Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
about
Role of cytochrome P450 in drug interactionsPharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain SocietyDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsNanomedicine in Central Nervous System (CNS) Disorders: A Present and Future ProspectiveAcute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice.Predicting in vivo drug interactions from in vitro drug discovery data.The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms.Treatment-resistant depression in late life.Depression and dementia: comorbidities, identification, and treatment.Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system.Citalopram in the treatment of depression and other potential uses in psychiatry.Absence of effect of stimulants on the phamacokinetics of desipramine in children.Acute dystonia induced by drug treatment.A case of risperidone overdose in early schizophrenia: a review of potential complications.Citalopram--a review of pharmacological and clinical effects.Tolerability and safety of fluvoxamine and other antidepressants.Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?A case study of postoperative delirium.Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.Risperidone-associated diabetes mellitus: a pharmacovigilance study.An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS.Newer antipsychotics: comparative review of drug interactions.Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders.Optimizing response to methadone maintenance treatment: use of higher-dose methadone.Retrospective use of PBPK modelling to understand a clinical drug-drug interaction between dextromethorphan and GSK1034702.Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.Selecting a Selective Serotonin Reuptake Inhibitor: Clinically Important Distinguishing Features.The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.Enantioselective analysis of fluoxetine in pharmaceutical formulations by capillary zone electrophoresis.Sudden cardiac death with clozapine and sertraline combination.Effect of fluconazole on the pharmacokinetics and pharmacodynamics of oral and rectal bromazepam: an application of electroencephalography as the pharmacodynamic method.Interaction of different antidepressants with acute and chronic methadone in mice, and possible clinical implications.Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers.Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report.Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement.
P2860
Q21245066-BA258C6F-FECB-4CB4-87FE-8EB54B231479Q24657295-BB86363E-6046-4EB1-B97C-AA2B7ED21A43Q28071256-B44EF2A5-4C97-427E-B9E9-75AAF65DD29DQ28075999-6EB49E8A-AE56-42FE-AA3D-F2307BBFDC1AQ30467213-404DA813-6BCF-4DEA-940B-535CEF49767CQ31011412-BFF21887-1719-4210-B7AF-884B0CD7DE6AQ33181987-9689DB7C-5BB9-460F-8D7F-C28F6F37FC84Q33254664-FE184DBE-660A-44E8-93A3-7A4410FDF660Q33609576-5D2D1040-2131-439B-8EFA-41C28D324793Q33609585-FCF6F0C4-FE75-45B1-8827-D78A8163BF3BQ33630990-4DDFA2D9-3D7C-445C-83A3-121F190499FDQ33677537-3B5AE80C-C2A2-4797-A665-E71777A764EBQ33677560-8A718809-9DE8-4237-9F19-BB50923F5A21Q33726345-6795B6AC-7530-4ED4-9202-11C367E7D7F0Q33922149-D1F2C41C-0BF0-4499-8022-F398EA2B7DA7Q33948515-B4B6F188-8FDB-47D8-AEB4-106BD07F4266Q33995120-768DF42F-68DC-4801-9EDA-56556C19BC14Q34119454-4E8971FE-FB35-4133-B50C-66784823BF59Q34146983-976E9D3E-8622-49F3-9425-72FB04350E7AQ34581169-320450F4-B039-4263-AD39-193CE9A7A914Q34756198-58B400A1-2BB5-4923-8B17-34EA08D0847EQ35160244-E9CF68EA-31FA-4B56-A32C-96F4FF25B675Q35967040-E007C1C2-5842-446E-8D24-E1C9EB9E0F96Q37610290-C9BBA29C-C0C5-414F-BA40-E714B905CCFBQ38366480-6ED7EF73-40DB-42AE-9F30-1A58986E1DDEQ38499496-34C6EE50-47A9-4051-BE8B-A7C60356948FQ39136867-82A649DA-B616-4FC1-9703-21CAEC037E42Q39143939-C7EDCC65-B28C-4D60-A093-D9FE4BB501DCQ39853590-C937368F-C55E-4112-B2C2-D876E76168DAQ40085236-FB5D58AB-0EB2-45B6-95DF-A3E896F32494Q42104550-85016A26-B496-4DBA-ABF5-2C7D997F28B1Q43695410-8A38AD45-555B-48FF-B1E0-35EDBB6E1F7DQ43878866-41EA917E-6FE2-43F8-A671-587C6E12FC08Q44993589-1D4A6083-47B0-4C7C-9500-095F86DFC432Q45117152-83A6B2B3-478C-4EDB-8244-B7A0226BB820Q45247035-E2B0A4F3-545F-44FD-960E-2EF66A370FB3Q47161733-816F77DB-93EB-47D7-A2D1-00456EEDFBB4
P2860
Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
description
1997 nî lūn-bûn
@nan
1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Selective serotonin reuptake i ...... itical review of the evidence.
@ast
Selective serotonin reuptake i ...... itical review of the evidence.
@en
Selective serotonin reuptake i ...... itical review of the evidence.
@nl
type
label
Selective serotonin reuptake i ...... itical review of the evidence.
@ast
Selective serotonin reuptake i ...... itical review of the evidence.
@en
Selective serotonin reuptake i ...... itical review of the evidence.
@nl
prefLabel
Selective serotonin reuptake i ...... itical review of the evidence.
@ast
Selective serotonin reuptake i ...... itical review of the evidence.
@en
Selective serotonin reuptake i ...... itical review of the evidence.
@nl
P2093
P1476
Selective serotonin reuptake i ...... itical review of the evidence.
@en
P2093
Brenmer KE
Naranjo CA
Sproule BA
P304
P356
10.2165/00003088-199733060-00004
P577
1997-12-01T00:00:00Z
P6179
1046553300